Pretransplantation combined therapy with plasmapheresis and rituximab in a second living-related kidney transplant pediatric recipient with a very high risk for focal segmental glomerulosclerosis recurrence

Pediatr Transplant. 2012 Nov;16(7):E286-90. doi: 10.1111/j.1399-3046.2011.01610.x. Epub 2011 Nov 30.


Prophylactic PP can provide some protection against post-transplantation recurrences of FSGS, but it cannot prevent recurrences in all cases. Therefore, new preventive therapies are needed. We report on a 7.9-yr-old girl treated with pretransplantation prophylactic combined therapy consisting of four sessions of PP and one dose of rituximab before a second living-related KTX. The patient had a very high risk of post-transplantation FSGS recurrence because this had occurred after the first KTX. During the 36 months since the second transplantation, she has had no evidence of proteinuria or significant infectious complications. Although our experience is too preliminary to draw any generalizable conclusions, pretransplantation combined therapy with PP and rituximab might be a possible option for the prevention of FSGS recurrence in very high-risk recipients undergoing living-donor KTXs.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal, Murine-Derived / therapeutic use*
  • Child
  • Disease Progression
  • Female
  • Glomerulosclerosis, Focal Segmental / therapy*
  • Graft Survival
  • Humans
  • Immunologic Factors / therapeutic use
  • Kidney Transplantation / methods*
  • Living Donors
  • Plasmapheresis / methods*
  • Renal Insufficiency / therapy
  • Reoperation
  • Rituximab
  • Secondary Prevention
  • Time Factors
  • Treatment Outcome


  • Antibodies, Monoclonal, Murine-Derived
  • Immunologic Factors
  • Rituximab